| Title | Development of novel Inhibitors of CXCL12 production as new medicines for cancer and inflammation. |
|---|
| Supervisors | Robin Plevin Kathryn McIntosh |
|---|
| Research Area | CLXL12, cancer, Nuclear factor kappa B, signalling, molecular. Cellular Basis of disease/Drug discovery |
|---|
| Description | CXCL12 is a chemokine known to affect a number of important cellular events. Recent studies have implicated it in a number of disease such as cancer, arthritis and atherosclerosis. Inhibitors of the receptor for CXCL12, CXCR4, have been developed but have been found to have limited clinical success. An alternative strategy is to prevent the expression of CXCL12 as a means to inhibit its function. Using an initial CXCL12 assay screen we have uncovered a number of potential novel inhibitors. The project will assess the site and mechanism of action of these inhibitors and assess their potential as novel drugs for treatment of disease. At the same time molecular approach will allow understanding of signalling events linked to CXCL12 to be explored. |
|---|
| Techniques Used | Cell culture, western blotting, imaging, gene array, FACS analysis, siRNA. |
|---|
| References | Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers. J Med Chem. 2017 Aug 24;60(16):7043-7066. doi: 10.1021/acs.jmedchem.7b00484. Epub 2017 Aug 15. |
|---|
| Conditions | Applicants should possess or be about to obtain a 1st class or 2:1 Honours degree or equivalent in Biology, Biochemistry or Pharmacology in addition to receipt of satisfactory references and an IELTS score of 6.5 where appropriate. |
|---|
| Bench Fee | Running costs of £10000 p.a. will be associated with this project in addition to University tuition fees. |
|---|
| | Apply Now |